Revance Therapeutics Inc
Revance Therapeutics Inc logo
RVNC

Revance Therapeutics Inc (RVNC)

$22.151.79%

Market is closed
– opens on 8 PM, 05 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$21.23
Day's Range
$22.33
$11.27
52-Week Range
$30.95
1 month return4.58%
3 month return10.2%
1 year return51.92%
5 year return14.81%

Company Information

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which provides an integrated smart payment solution that supports aesthetic practice management, practice economics and practice loyalty. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences.
OrganizationRevance Therapeutics Inc
Employees495
CEOMr. Mark J. Foley
IndustryHealth Technology

Analyst Recommendation

based on 10 analysts ratings

Buy
90%
Buy
10%
Hold
0%
Sell

Based on 10 Wall street analysts offering stock ratings for Revance Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 53.5%

Current

$22.15

Target

$34.0

Recommendation Trend

Based on 10 analyst

Current1M Ago3M Ago
Buy
9
15
14
Hold
1
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
1.8B
Book Value
$1.77
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-4.04
PEG Ratio
-0.64
Wall Street Target Price
34.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
12.99
Enterprise Value
1.9B
Enterprise Value/Revenue
17.89
Enterprise Value/Ebitda
-8.36

Technicals

Beta
0.54
50 Day MA
24.25
200 Day MA
18.9

Institutional Holdings

Capital World Investors

9.78%

JPMorgan Chase & Co

8.13%

Palo Alto Investors, LLC

5.35%

Vanguard Group Inc

5.24%

Polar Capital Holdings PLC

3.79%

Franklin Resources Inc

2.88%

Discover more

Frequently Asked Questions

What is Revance Therapeutics Inc share price today?

Can Indians buy Revance Therapeutics Inc shares?

How can I buy Revance Therapeutics Inc shares from India?

Can Fractional shares of Revance Therapeutics Inc be purchased?

What are the documents required to start investing in Revance Therapeutics Inc stocks?

What are today’s High and Low prices of Revance Therapeutics Inc?

What are today’s traded volumes of Revance Therapeutics Inc?

What is today’s market capitalisation of Revance Therapeutics Inc?

What is the 52 Week High and Low Range of Revance Therapeutics Inc?

How much percentage Revance Therapeutics Inc is down from its 52 Week High?

How much percentage Revance Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Revance Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Revance Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*